Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms.

Matsubara E, Takamura A, Okamoto Y, Oono H, Nakata T, Wakasaya Y, Kawarabayashi T, Shoji M.

Biomed Res Int. 2013;2013:984041. doi: 10.1155/2013/984041. Epub 2013 Aug 26.

2.

Sortilin is required for toxic action of Aβ oligomers (AβOs): extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways.

Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, Oddo S, Laferla FM, Shoji M, Matsubara E.

Life Sci. 2012 Dec 10;91(23-24):1177-86. doi: 10.1016/j.lfs.2012.04.038. Epub 2012 May 3.

PMID:
22579764
3.

Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.

Viola KL, Klein WL.

Acta Neuropathol. 2015 Feb;129(2):183-206. doi: 10.1007/s00401-015-1386-3. Epub 2015 Jan 22. Review.

4.

Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.

Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW.

J Neurosci. 2008 May 14;28(20):5149-58. doi: 10.1523/JNEUROSCI.4878-07.2008.

5.

Elucidating molecular mass and shape of a neurotoxic Aβ oligomer.

Sebollela A, Mustata GM, Luo K, Velasco PT, Viola KL, Cline EN, Shekhawat GS, Wilcox KC, Dravid VP, Klein WL.

ACS Chem Neurosci. 2014 Dec 17;5(12):1238-45. doi: 10.1021/cn500156r. Epub 2014 Nov 7.

6.

Alzheimer's Aβ interacts with cellular prion protein inducing neuronal membrane damage and synaptotoxicity.

Peters C, Espinoza MP, Gallegos S, Opazo C, Aguayo LG.

Neurobiol Aging. 2015 Mar;36(3):1369-77. doi: 10.1016/j.neurobiolaging.2014.11.019. Epub 2014 Dec 16.

PMID:
25599875
7.

Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.

Cho JE, Kim JR.

Recent Pat CNS Drug Discov. 2011 Sep 1;6(3):222-33. Review.

PMID:
21834780
8.

Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.

De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST.

FASEB J. 2004 Sep;18(12):1366-72.

PMID:
15333579
9.

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM.

J Biol Chem. 2005 Feb 18;280(7):5892-901. Epub 2004 Dec 7.

10.

Non-toxic conformer of amyloid β may suppress amyloid β-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease.

Izuo N, Murakami K, Sato M, Iwasaki M, Izumi Y, Shimizu T, Akaike A, Irie K, Kume T.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):1-5. doi: 10.1016/j.bbrc.2013.05.106. Epub 2013 Jun 4.

PMID:
23747423
11.

Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse.

Takamura A, Okamoto Y, Kawarabayashi T, Yokoseki T, Shibata M, Mouri A, Nabeshima T, Sun H, Abe K, Urisu T, Yamamoto N, Shoji M, Yanagisawa K, Michikawa M, Matsubara E.

Mol Neurodegener. 2011 Mar 6;6(1):20. doi: 10.1186/1750-1326-6-20.

12.

Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation.

Brogi S, Butini S, Maramai S, Colombo R, Verga L, Lanni C, De Lorenzi E, Lamponi S, Andreassi M, Bartolini M, Andrisano V, Novellino E, Campiani G, Brindisi M, Gemma S.

CNS Neurosci Ther. 2014 Jul;20(7):624-32. doi: 10.1111/cns.12290.

PMID:
24935788
13.

An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway.

Marín-Argany M, Rivera-Hernández G, Martí J, Villegas S.

Biochem J. 2011 Jul 1;437(1):25-34. doi: 10.1042/BJ20101712.

PMID:
21501114
14.

Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease.

Itkin A, Dupres V, Dufrêne YF, Bechinger B, Ruysschaert JM, Raussens V.

PLoS One. 2011 Mar 28;6(3):e18250. doi: 10.1371/journal.pone.0018250.

15.

Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.

Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Hernandez C, Barrett AD, Dineley K, Kayed R.

J Neurosci. 2015 Mar 25;35(12):4857-68. doi: 10.1523/JNEUROSCI.4989-14.2015.

16.

Aβ oligomer-induced synapse degeneration in Alzheimer's disease.

Wilcox KC, Lacor PN, Pitt J, Klein WL.

Cell Mol Neurobiol. 2011 Aug;31(6):939-48. doi: 10.1007/s10571-011-9691-4. Epub 2011 May 3. Review.

17.

Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.

Murakami K.

Biosci Biotechnol Biochem. 2014;78(8):1293-305. doi: 10.1080/09168451.2014.940275. Review.

PMID:
25130729
18.

Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease.

Zetterberg H, Blennow K.

Alzheimers Dement. 2013 Jul;9(4):459-62. doi: 10.1016/j.jalz.2012.07.002. Epub 2012 Nov 14. Review.

PMID:
23159047
19.

Inhibition of amyloid-β aggregation in Alzheimer's disease.

Wang Q, Yu X, Li L, Zheng J.

Curr Pharm Des. 2014;20(8):1223-43. Review.

PMID:
23713775
20.

Interaction of Alzheimer's β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation.

Di Scala C, Chahinian H, Yahi N, Garmy N, Fantini J.

Biochemistry. 2014 Jul 22;53(28):4489-502. doi: 10.1021/bi500373k. Epub 2014 Jul 11. Review.

PMID:
25000142

Supplemental Content

Support Center